Creabilis rounds up $30M

CompanyAmount/RoundLead InvestorsDescription

Creabilis Therapeutics
Sofinnova Partners

The money is earmarked for three mid-stage studies of CT327 for psoriasis and dermatitis and CT200, which is being developed for Behcet's Disease.

IRX Therapeutics
New York
Existing investors

The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment.

Inimex Pharmaceuticals
Morningside Venture Investments

The company is launching the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and assessing IDR drugs in a range of disease models.

Creabilis rounds up $30M

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.